-
-
-
-
-
-
-
Genmab closes $2.5 billion debt offering to fund Merus acquisition
-
-
-
-
-
-
-
Genmab launches $97 per share tender offer for Merus
-
-
-
-
-
-
-
Genmab agrees to acquire Merus for $8 billion in all-cash deal
-
-
-
-
-
-
-
Genmab Updates 2024 Financial Guidance
-
-
-
-
-
-
-
Genmab Publishes 2023 Annual Report
-
-
-
-
-
-
-
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
-
-
-
-
-
-
-
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
1,177,108 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

